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Abstract
Background: Inhaled corticosteroids (ICS) have been associated with decreased lung cancer risk. However, they
have been associated with pulmonary infections (tuberculosis [TB] and pneumonia) in patients with chronic
obstructive pulmonary disease (COPD). TB and pneumonia have increased lung cancer risk. The association
between post-ICS pulmonary infections and lung cancer remains unclear.
Methods: We conducted a retrospective cohort study from 2003 to 2010 using the Taiwan National Health
Insurance Research Database. Among the 1,089,955 patients with COPD, we identified 8813 new users of ICS
prescribed for a period of 3 months or more and 35,252 non-ICS users who were randomly matched for sex,
age and date of ICS use from 2003 to 2005. Cox proportional hazard regression was used to estimate the hazard
ratio (HR) of pulmonary infections in patients with/without ICS use.
Results: The HRs for lung cancer in ICS users with sequential lung infections were as follows; 2.42 (95 % confidence
interval [CI], 1.28–4.58) for individuals with TB, 2.37 (95 % CI, 1.01–5.54) for TB and pneumonia, and 1.17(95 % CI,
0.69–1.98) for those with pneumonia. For non-ICS users with pulmonary infections, the HRs were 1.68 (95 % CI,
0.78–3.65) for individual with TB and pneumonia, 1.42 (95 % CI, 0.89–2.26) for TB, and 0.95 (95 % CI, 0.62–1.46)
for individuals with pneumonia.
Conclusions: COPD patients with TB /or pneumonia who used ICS had increased risk of lung cancer. Because the
overall prognosis of lung cancer remains poor, screening tests are recommended for patients with these conditions.
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Background
The prevalence of chronic obstructive pulmonary disease
(COPD) in Taiwan is 2.48 % [1]. COPD is a common
chronic inflammatory airway disease and is associated
with lung cancer [2, 3]. Inhaled (ICS) and oral cortico-
steroids (OCS) have been used to reduced airway inflam-
mation and acute exacerbations [4–6]. Lee et al.
conducted a nested case-control study with new adult
users of ICS. Results showed that ICS use led to a
reduced risk of lung cancer [7]. In a separate study, ICS
has also reduced lung cancer risk among COPD patients
[8] and those who quit smoking [9].
However, there is a close association between ICS use,
pulmonary tuberculosis (TB) [10] and pneumonia [11].
TB [12] and pneumonia [13] have been associated with
increased risk of lung cancer. Coexistence of COPD and
TB correlates with increased incidence and mortality of
lung cancer [2, 14]. The association between post-ICS
pulmonary infections and lung cancer in patients with
COPD remains unclear. In this study, we evaluated the
association between post-ICS pulmonary infections
and lung cancer using the National Health Insurance
Research Database (NHIRD).
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Data from the NHIRD, Taiwan Cancer Registry Database
(TCRD) and the National Death Registry Database
(NDRD) were linked in this retrospective cohort study.
The NHIRD provide a comprehensive health care infor-
mation including diagnoses, clinical visits, admission
and prescriptions. The multiple databases were used to
assess the age at cancer onset, person-month follow-up,
death, survival time, and misdiagnosis. Personal informa-
tion including ethnicity, family history, lifestyle, occupa-
tion, and habits such as smoking and alcohol intake was
not available in the NHIRD.
Ethics
This study was approved by the Institutional Review
Board of the Chung-Shan Medical University Hospital.
The informed consent was waived by the Institutional
Review Board as the source data were encrypted and the
data extracted were anonymous.
COPD patients with ICS use
This study enrolled patients with COPD from 2001 to
2005 who were free from lung cancer before 2002.
Excluded were COPD patients who used ICS before 2002
and those with incomplete information. Also exclude were
patients below 20 and over 100 years of age. We identified
patients who were prescribed ICS and OCS from 2003 to
2005 using the inpatient and outpatient medical records.
Information regarding ICS and OCS prescription were
also collected, including prescription dates, daily dose
prescribed and the duration of prescription. The ICS
included beclomethasone, budesonide, fluticasone and
ciclesonide whether used alone or in a combination
inhaler with an inhaled β2 agonist. Eligible participants
included COPD patients who were first time users of ICS
prescribed for a period of 3 months or more. The date of
the first use of ICS was called the index date.
For each new ICS user, four controls were randomly
matched for sex, age and index date without replication
from COPD patients who were not exposed to ICS. The
eligible participants (ICS and non-ICS users) were
followed up until the development of lung cancer, loss to
follow-up, death, or the end of the year 2010.
Post- ICS pulmonary TB and pneumonia
Pulmonary TB was defined by a compatible International
Classification of Diseases, Ninth Revision, Clinical Modi-
fication (ICD-9-CM) code (010-012, 018, and137) with
either two outpatient visits or one admission after the
index date. Cases of pneumonia were using the ICD-9-CM
codes: 480–486, and 487.0. Patients diagnosed with
TB or pneumonia before or within 3 months after the
index date were also excluded.
Outcomes
The primary outcome was the first diagnosis of lung
cancer during the follow-up. Lung cancer was defined by
a compatible ICD-9-CM code 162. The cell types of lung
cancer were further identified using the TCRD. Further
exclusions included patients who either died or had lung
cancer within 2 years of the index date.
Medications
To define OCS use, patients who took a cumulative dose
of 1680 mg (or 60 mg daily for 4 weeks) of hydrocor-
tisone equivalents or more during 1 year after the index
date were enrolled [10]. All OCS received during follow-
up were converted to the equivalent dose of hydrocor-
tisone in milligrams (4 mg of hydrocortisone = 5 mg of
cortisone = 1 mg of prednisolone = 0.8 mg methylpred-
nisolone = 0.8 mg of triamcinolone = 0.4 mg of para-
methasone = 0.15 mg of betamethasone = 0.15 mg of
dexamethasone) [15].
In addition, we also adjusted for the severity of COPD
medications, including short-acting inhaled β2 agonists
(SABAs; salbutamol, fenoterol, procaterol, or terbutaline),
long-acting inhaled β2 agonists (LABAs; salmeterol,
formoterol, indacaterol, or olodaterol), and theophylline.
Variables of exposure
Comorbidities were defined by either two outpatient
visits or one hospitalization in 1 year. They included
COPD (ICD-9-CM: 490, 491, 492, 494, and 496), chronic
kidney disease (ICD-9-CM: 585 and 586), diabetes melli-
tus (ICD-9-CM: 250), hyperlipidemia (ICD-9-CM: 272),
liver cirrhosis (ICD-9-CM: 571.2, 571.5, and 571.6),
smoking-related cancers (ICD-9-CM: 140–150, 157,
160–161, and 189), autoimmune disease (ICD-9-CM:
710 and 714), atopic dermatitis (ICD-9-CM: 691), and
rhinosinusitis (ICD-9-CM codes: 472.0, 473, and 477).
In order to assess the severity of COPD, the number
of outpatient and inpatients visits for respiratory diseases
during 2 years after the index date were evaluated. How-
ever, information regarding lifestyle behavior such as
smoking was not available in the NHIRD, hence preven-
ting direct adjustment for possible confounders.
Statistical analysis
Data analysis was made using the SAS 9.3 software
(SAS Institute, Cary, NC). Differences in baseline
characteristics and comorbidities between ICS and
non-ICS users were compared using the Chi-square
test and t-test. Kaplan-Meier survival plots were used to
evaluate the effect of predictor variables on lung cancer
at the univariate level. ICS users and non-users were
compared using the log-rank test. The adjusted hazard
ratios (HRs) and 95 % confidence intervals (CIs) of the
lung cancer risk factors were calculated using multivariate
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Cox proportional hazards regression modeling. A P-value
of less than 0.05 was considered to be statistically significant.
Results
We identified 1,196,878 patients with COPD from 2001
to 2005 who were not diagnosed with lung cancer before
2002. We excluded 12,067 patients who received ICS
before 2002 and 94,856 patients with incomplete infor-
mation including sex and registry data. We enrolled
15,714 COPD patients who used ICS for a period of
3 months or more. Further exclusion included the
following: participants who died or those that were diag-
nosed with lung cancer within 2 year after the index date
(n = 1970), individuals diagnosed with TB or pneumonia
before or 3 months after the index date (n = 4481),
people below 20 and above 100 years of age (n = 187),
and ICS users without matched controls (n = 263).
Therefore, 8813 new users of ICS were matched with
35,252 non-users (Fig. 1).
Information on demographic characteristics, medica-
tions, comorbidities, and follow-up durations of the study
participants are shown in Table 1. In total, 179 ICS users
(i.e. no lung infection, 143 cases; pneumonia, 19; TB, 11,
and TB + pneumonia, 6) and 496 non-users had lung
cancer (no lung infection, 442 cases; pneumonia, 28; TB,
19, and TB + pneumonia, 7).
Kaplan-Meier plots for TB, pneumonia, and TB +
pneumonia stratified by ICS use are presented in Fig. 2.
The 5-year cumulative incidence of lung cancers was
significantly higher in ICS users without lung infection
than their non-user counterparts (2.3 versus 1.6 %;
p = 0.0008), and in users with TB than their non-user
counterparts (7.5 versus 3.1 %; p = 0.0214).
Table 2 shows the adjusted HRs of lung cancer in
COPD patients with TB, pneumonia and TB + pneumonia
who were users and non-users of ICS. Post-ICS TB
and TB + pneumonia significantly increased the risk of
lung cancer. The respective HRs were 2.42 (95 % CI,
1.28–4.58) and 2.37 (95 % CI, 1.01–5.54). There was
no significant increase in lung cancer risk among ICS
users without lung infection (HR, 0.88; 95 % CI,
0.67–1.14). There was no significant association between
lung cancer and pulmonary infections such as TB
(HR, 1.42; 95 % CI, 0.89–2.26), pneumonia (HR, 0.95;
95 % CI, 0.62–1.46) and TB + pneumonia (HR, 1.68;
95 % CI, 0.78–3.65) among the non-ICS users. No
Fig. 1 Flow diagram of the enrollment process. COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid, TB, tuberculosis
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significant interaction was found between ICS use, TB
(p = 0.084), pneumonia (p = 0.259), and TB + pneumonia
(p = 0.386) (Table 3).
Discussion
Corticosteroids are used to control airway inflammation
in patients with COPD. They have also increased the
risk of pulmonary TB and pneumonia [10, 11]. Many
studies have documented a possible link between chronic
inflammation, infection and lung cancer [2, 16, 17].
However, little is known about post-ICS pulmonary
infections and lung cancer. Results from this study
suggest that post-ICS TB with/without pneumonia
may serve as risk factors for lung cancer.
COPD, a chronic disease characterized by a chronic
inflammation of the lower airways has been associated
with lung cancer [18]. The presence of moderate-to-
severe obstructive pulmonary function was associated
with a higher risk of lung cancer (HR, 2.8; 95 % CI,
1.8–4.4) [19]. Denholm et al. pooled information from
seven case–control studies with 12,739 case subjects
and 14,945 controls and found that chronic bronchitis
and emphysema were positively associated lung cancer in
men at odds ratios (ORs) of 1.33 (95 % CI, 1.20–1.48) and
1.50 (95 % CI, 1.21–1.87), respectively [20]. In a study
comprising 15,219,024 Taiwanese residents, an increased
risk of lung cancer was found in men (HR, 1.56; 95 % CI,
1.51–1.61) and women (HR, 1.33; 95 % CI, 1.26–1.10)
with COPD [3].
ICS has been established in the treatment of COPD
especially in symptomatic patients who experience useful
gains in the quality of life, reduction in acute exacer-
bations, and an attenuation of the yearly rate of deterio-
ration in lung function [21]. Acute severe exacerbations
require the addition of systemic corticosteroids to con-
trol respiratory symptoms and improve lung function









None 7823 (88.7) 32,694 (92.7)
Pneumonia 703 (8.0) 1654 (4.7)
TB 182 (2.1) 678 (1.9)
TB + pneumonia 105 (1.2) 226 (0.7)
Medications (%)
OCS 3376 (38.3) 1992 (5.7) <0.001
LABA 4236 (48.1) 1186 (3.4) <0.001
SABA 7313 (83.0) 6244 (17.7) <0.001
Theophylline 8305 (94.2) 19,876 (56.4) <0.001
Statins 1368 (15.5) 5591 (15.7) 0.437
Aspirin 2652 (30.1) 12,203 (34.6) <0.001
Sex (%) 1.000
Men 6078 (69.0) 24,312 (69.0)
Women 2735 (31.0) 10,940 (31.0)
Age (years, %) 1.000
20–39 270 (3.1) 1080 (3.1)
40–59 1875 (21.3) 7500 (21.3)
60–79 5328 (60.4) 21,312 (60.4)
≧80 1340 (15.2) 5360 (15.2)
Comorbidities (%)
Diabetes 254 (2.9) 1192 (3.4) 0.019
Hyperlipidemia 1627 (18.5) 7423 (21.1) <0.001
Chronic kidney disease 1472 (16.7) 7028 (19.9) <0.001
Smoking-related cancers 124 (1.4) 656 (1.9) 0.004
Liver cirrhosis 96 (1.1) 423 (1.2) 0.389
Autoimmune disease 280 (3.2) 1002 (2.8) 0.095
Atopic dermatitis 162 (1.8) 734 (2.1) 0.147
Rhinosinusitis 3955 (44.9) 6739 (19.1) <0.001
No. of outpatient visits for
respiratory diseases within 2 years
after index date (%)a
24.5 ± 14.5 6.0 ± 9.6 <0.001
≤ 15 2054 (23.3) 30,735 (87.2) <0.001
> 15 6759 (76.7) 4517 (12.8)
No. of inpatient visits for
respiratory diseases within 2 years
after index date (%)a
0.8 ± 1.7 0.2 ± 0.8 <0.001
0 5779 (65.6) 30,661 (87.0) <0.001
≥ 1 3034 (34.4) 4591 (13.0)
Urbanization (%) <0.001
High 4934 (56.0) 18,971 (53.8)
Mid 2830 (32.1) 11,441 (32.5)
Low 1049 (11.9) 4840 (13.7)
Table 1 Characteristics of the Study Population (Continued)
Death in 2004–2008 (%) 1118 (12.7) 3590 (10.2) <0.001
Follow-up time
(person-months)
4.2 × 105 17.4 × 105
No. of lung cancer 179 496
Incidence rate
(per 105 person months)
(95 % C.I.)
42.2 (36.5–48.9) 28.5 (26.1–31.1) <0.001
Histologic type (%) 0.148
Squamous cell carcinoma 34 (19.0) 128 (25.8)
Adenocarcinoma 76 (42.5) 173 (34.9)
Small cell carcinoma 24 (13.4) 57 (11.5)
Others 45 (25.1) 138 (27.8)
CI confidence interval, HR hazard ratio, ICS inhaled corticosteroid, LABA
long-acting inhaled beta-agonist, OCS oral corticosteroid, SABA short-acting
beta-agonist, TB pulmonary tuberculosis
aIndex date was defined as the date of initiation of ICS
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[22]. In an analysis including new adult ICS users
(9177 cases and 37,048 controls), ICS use had a significant
linear association with a decreased lung cancer incidence
(OR, 0.79; 95 % CI, 0.69–0.90) [7]. In an epidemiologic
study involving 10,474 veterans with COPD, a dose-
response relationship was observed between ICS exposure
and lung cancer [8]. Participants (n = 219) who received
high-dose ICS (triamcinolone ≧1200 ug/day) had a
decrease risk of lung cancer (HR, 0.39; 95 % CI,
0.16–0.96). After excluding subjects who had a lung
cancer diagnosis within 1 year after enrollment, there was
no significant dose-response reduction in lung cancer risk
even at the higher doses of ICS. A retrospective cohort
study of patients with a first-time diagnosis of COPD who
had quit smoking and were regular users of ICS found a
risk reduction when assessing a dose-response relation-
ship of lung cancer [9]. The HRs were 0.88 (95 % CI,
0.51–1.52) and 0.51 (95 % CI, 0.30–0.84) in ICS users with
1–2 and 3 or more prescriptions/year, respectively. In
our study, there was no decreased risk of lung cancer
in ICS users with no pulmonary infections.
Immunosuppressive effects of glucocorticoids include
inhibition of macrophage differentiation, production of
cytokines, tumoricidal and microbicidal activities of
activated macrophages, and T-cell activation [23]. The
joint statement of the American Thoracic Society and
the Centers for Disease Control and Prevention acknow-
ledges that an administration of prednisone ≧ 15 mg/day
(or its equivalent of another steroids) for a period of
1 month or more serves as a risk factor for TB [24]. A
retrospective cohort study reported that ICS use was
an independent risk factor for the development of
pulmonary TB in patients who had normal chest radio-
graphs (HR, 9.08; 95 % CI, 1.01–81.43) and in those
who had radiologic findings of previous pulmonary TB
(HR, 24.95; 95 % CI, 3.09–201.37) [25]. In a nested case-
control study with 4139 TB cases and 20,583 controls,
ICS use had a significant linear association with increased
risk of TB: The OR was 1.20 (95 % CI, 1.08–1.34) [10].
In Taiwan, Chung et al. reported that there was a
multiplicatively increased risk of TB in patients who used
ICS and OCS compared to their non-user counterparts
Fig. 2 Cumulative incidence of lung cancer in ICS users and the comparison cohorts stratified by the presence of non-lung infection (a), TB (b),
pneumonia (c), and TB+ pneumonia (d). ICS, inhaled corticosteroid; TB, tuberculosis
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(OR, 4.31; 95 % CI, 3.39–5.49) [26]. Moreover, ICS has
been associated with pneumonia in patients with COPD.
In a nested case-control study of patients≧65 years,
current users of ICS were 1.38 (OR, 1.38; 95 % CI,
1.31–1.45) times more likely to have a hospitalization
of pneumonia [11]. A study has reported a gradual
decrease in acute exacerbation rate of COPD and an
increased incidence of pneumonia after ICS use (i.e. from
0.10 to 0.21 event/person-year) [27].
Patients with newly diagnosed TB were at increased
risk of lung cancer with an adjusted HR of 3.32
(95 % CI, 2.70–4.09) [28]. Nonsmokers with TB had a
significant association with lung squamous cell carcinoma
and adenocarcinoma for both genders, whereas male
smokers with TB were associated with squamous cell
carcinoma, small cell carcinoma, and adenocarcinoma,
and female smokers with TB were associated with adeno-
carcinoma [29]. In a separate study that recruited patients
with pneumonia (22,034 patients and 88,136 matched
controls), pneumonia was associated with an increased
risk of lung cancer (HR, 4.24; 95 % CI, 3.96–4.55) [13]. In
a meta-analysis, the relative risks of lung cancer in
patients with a previous history of pneumonia and TB
were 1.43 (95 % CI, 1.22–1.68) and 1.76 (95 % CI,
1.49–2.08), respectively [30]. When the analysis was
restricted to nonsmokers, effects remained significant for
pneumonia 1.36 (95 % CI, 1.10–1.69) and TB 1.90
(95 % CI, 1.45–2.50). In this study, increased risks of
lung cancer were observed mainly in patients with
post-ICS TB and TB + pneumonia.
Jian et al. reported a stronger association between
coexisting COPD and TB and lung cancer [2]. The
HRs were 2.42 (95 % CI, 2.18–2.69) in men and 2.41
(95 % CI,1.90–3.07) in women. Biologically, the additive
effects of ICS, COPD, pneumonia, and TB on lung
cancer may be explained by corticosteroids-induced
Table 2 Hazard Ratio and 95 % Confidence Intervals of Lung
Cancer According to ICS and Pulmonary Infection Combinations
in Patients with COPD
All patients with COPD
HR (95 % CI) P-value
Pulmonary infection combinations
None Reference
Only ICS 0.88 (0.67–1.14) 0.314
Only pneumonia 0.95 (0.62–1.46) 0.818
Only TB 1.42 (0.89–2.26) 0.145
TB+pneumonia 1.68 (0.78–3.65) 0.187
Post-ICS pneumonia 1.17 (0.69–1.98) 0.554
Post-ICS TB 2.42 (1.28–4.58) 0.007
Post-ICS TB+pneumonia 2.37 (1.01–5.54) 0.046
Medications
OCS 0.91 (0.72–1.16) 0.442
LABA 1.18 (0.93–1.50) 0.177
SABA 1.32 (1.07–1.64) 0.010
Theophylline 1.21 (0.99–1.48) 0.052
Statins 1.05 (0.82–1.35) 0.704
Aspirin 0.89 (0.76–1.05) 0.173
Sex





60–79 4.69 (3.28–6.69) <0.001
≧80 6.47 (4.42–9.48) <0.001
Urbanization
High Reference
Mid 1.05 (0.89–1.24) 0.575
Low 0.97 (0.77–1.23) 0.799
Comorbidities
Chronic kidney disease 1.35 (0.94–1.93) 0.102
Diabetes 0.99 (0.82–1.21) 0.967
Hyperlipidemia 1.08 (0.85–1.36) 0.544
Liver cirrhosis 0.84 (0.43–1.62) 0.599
Smoking-related cancers 1.57 (0.91–2.73) 0.107
Autoimmune disease 1.57 (1.07–2.32) 0.022
Atopy dermatitis 0.67 (0.36–1.25) 0.208
Rhinosinusitis 0.90 (0.75–1.08) 0.263
No. of outpatient visits for respiratory diseases within 2 years after index datea
≤15 Reference
>15 1.27 (1.03–1.56) 0.025
No. of inpatient visits for respiratory diseases within 2 years after index datea
0 Reference
≥1 1.07 (0.85–1.35) 0.582
Reference was defined as the reference group
CI confidence interval, COPD chronic obstructive pulmonary disease, HR hazard
ratio, ICS inhaled corticosteroid, LABA long-acting inhaled beta-agonist, OCS
oral corticosteroid, SABA short-acting beta-agonist, TB pulmonary tuberculosis
aIndex date was defined as the date of initiation of ICS
Table 3 Interaction between ICS use and lung infections






No lung infection 1 0.89 (0.68–1.16) 0.084
TB 1.42 (0.89–2.26) 2.48 (1.31–4.72)
Model 2
No lung infection 1 0.88 (0.67–1.15) 0.259
Pneumonia 0.93 (0.60–1.44) 1.17 (0.69–1.99)
Model 3
No lung infection 1 0.88 (0.67–1.16) 0.386
TB+pneumonia 1.65 (0.76–3.58) 2.38 (1.01–5.58)
Each model was adjusted by sex, age, medications, comorbidities, inpatient
and outpatient visits for respiratory diseases, and urbanization
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compromised immune clearance of Mycobacterium
tuberculosis, bacteria and malignant cells, and COPD
and TB-related chronic inflammatory processes of the
lung. More studies ought to be conducted to investigate
the association between post-ICS pulmonary infections
and lung cancer.
This study had several strengths. First, the sample size
was large and the period of follow-up was long, hence
reducing the likelihood of selection biases. Second, lung
cancer was confirmed histologically, hence allowing the
little possibility of misclassification. Third, with at least
2 years from the initiation of ICS and diagnosis of lung
cancer, the chances of misclassifications were less.
Nevertheless, there were certain limitations. First,
information on medication were assessed solely by
refills, not by whether the subjects actually used the
medication that were prescribed. Second, information
regarding laboratory and image findings including air-
flow obstruction by spirometry and chest X-ray findings
for TB were not available in the NHIRD. Third, frequent
hospital visits might have led to a higher detection rate
of TB and early-stage lung cancer. Fourth, the databases
do not contain detailed information regarding smoking
history, radon exposure, occupational exposures, diet
preference, and family history, all of which may be risk
factors for lung cancer. When looking at COPD and
lung cancer risk, pack-years of cigarette smoking is
critical.
Conclusions
We found that post-ICS TB with/without pneumonia
conferred a higher risk of lung cancer in COPD patients.
Because of the high mortality of lung cancer, cancer
screening is recommended for COPD patients with
post-ICS TB with/without pneumonia.
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CI: Confidence interval; COPD: Chronic obstructive pulmonary disease;
HR: Hazard ratio; ICD-9-CM: International classification of diseases, ninth
revision, clinical modification code; ICS: Inhaled corticosteroid; LABA:
Long-acting inhaled β2 agonists; NDRD: National death registry database;
NHIRD: National Health Insurance Research Database; OCS: Oral
corticosteroid; OR: Odds ratio; RR: Relative risk; SABA: Short-acting inhaled β2
agonists; TB: Tuberculosis; TCRD: Taiwan cancer registry database
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